03rd week of 2013 patent applcation highlights part 29 |
Patent application number | Title | Published |
20130017110 | DIAPHRAGM PUMP USING DUCKBILL AND OTHER TYPES OF VALVESAANM VILLAGOMEZ; ManuelAACI CoronaAAST CAAACO USAAGP VILLAGOMEZ; Manuel Corona CA USAANM MEZA; Humberto V.AACI TustinAAST CAAACO USAAGP MEZA; Humberto V. Tustin CA USAANM PHILLIPS; David L.AACI Santa AnaAAST CAAACO USAAGP PHILLIPS; David L. Santa Ana CA US - A diaphragm pump is provided that features a valve housing configured with inlet openings and outlet openings; inlet duckbill check valve assemblies, each configured to be arranged in a respective inlet opening; and outlet duckbill check valve assemblies, each configured to be arranged in a respective outlet opening; each duckbill check valve assembly comprising: a duckbill check valve seat configured with an end having a slit to open to provide the fluid and particulate, and to close to prevent the backflow of the fluid and particulate; and a duckbill check valve support having a base portion configured to be inserted inside the duckbill check valve seat, and having a W-shaped portion configured with an opening to pass the fluid and particulate through the duckbill check valve support to the duckbill check valve seat and also configured to provide support for walls of the duckbill check valve seat in response to back pressure caused by the fluid and particulate. | 2013-01-17 |
20130017111 | SCROLL DEVICE FOR COMPRESSION OR EXPANSIONAANM Kane; MalickAACI EcublensAACO CHAAGP Kane; Malick Ecublens CHAANM Cretegny; DaniloAACI RenensAACO CHAAGP Cretegny; Danilo Renens CHAANM Merminod; AntoineAACI GimelAACO CHAAGP Merminod; Antoine Gimel CH - A device for varying pressure of a fluid comprising a scroll case ( | 2013-01-17 |
20130017112 | CONTROL CIRCUIT FOR TRANSMISSION VARIABLE DISPLACEMENT PUMP WITH IMPROVED EFFICIENCY - The present disclosure relates to a control circuit for a variable displacement pump in a vehicle transmission, including: a regulator valve configured to regulate displacement control fluid to the variable displacement pump; and a response limiter in communication with the regulator valve, configured to mitigate pressure oscillations in the control circuit. | 2013-01-17 |
20130017113 | CONTAINED SHAFT SPRING LOADAANM Walgren; Timothy P.AACI ByronAAST ILAACO USAAGP Walgren; Timothy P. Byron IL USAANM Heitz; Steven A.AACI RockfordAAST ILAACO USAAGP Heitz; Steven A. Rockford IL US - An input shaft assembly is movable along an axis to absorb external impact loads. A biasing member exerts an axial load in a direction counter to potential impact loads. A stop is provided to control the application of biasing loads to control application of such axial load. | 2013-01-17 |
20130017114 | Fluid MachineAANM Nakamura; ShinjiAACI Isesaki-shiAACO JPAAGP Nakamura; Shinji Isesaki-shi JPAANM Wada; HirofumiAACI Isesaki-shiAACO JPAAGP Wada; Hirofumi Isesaki-shi JP - A fluid machine ( | 2013-01-17 |
20130017115 | METHOD OF PRODUCING POROUS VALVE METAL THIN FILM AND THIN FILM PRODUCED THEREBY - Provided are a porous valve metal thin film having a great surface area, a method for the production thereof, and a thin film capacitor having a great capacity density utilizing the thin film as an anode. The porous valve metal thin film is produced by preparing a thin film in which a valve metal and a hetero-phase component have a particle diameter within a range of from 1 nm to 1 μm and the valve metal and the hetero-phase component are uniformly distributed, subjecting the thin film to a heat treatment so as to adjust the particle diameter and to appropriately sinter the film, and removing the hetero-phase portion. | 2013-01-17 |
20130017116 | FERRITIC STAINLESS STEEL SHEET EXCELLENT IN SURFACE GLOSS AND CORROSION RESISTANCE AND METHOD FOR PRODUCING SAMEAANM Hatano; MasaharuAACI Chiyoda-kuAACO JPAAGP Hatano; Masaharu Chiyoda-ku JPAANM Yamagishi; AkihitoAACI Chiyoda-kuAACO JPAAGP Yamagishi; Akihito Chiyoda-ku JPAANM Takahata; ShigenoriAACI Chiyoda-kuAACO JPAAGP Takahata; Shigenori Chiyoda-ku JPAANM Ishimaru; EiichiroAACI Chiyoda-kuAACO JPAAGP Ishimaru; Eiichiro Chiyoda-ku JP - The stainless steel sheet according to the present invention is a ferritic stainless steel which is comprised of, by mass %, C: 0.001 to 0.03%, Si: 0.01 to 1.0%, Mn: 0.01 to 1.5%, P: 0.005 to 0.05%, S: 0.0001 to 0.01%, Cr: 12 to 16%, N: 0.001 to 0.03%, Nb: 0.05 to 0.3%, Ti: 0.03 to 0.15%, Al: 0.005 to 0.5%, Sn: 0.01 to 1.0%, and has the remainder of Fe and unavoidable impurities and satisfies the relationship of 1≦Nb/Ti≦3.5. The method comprises heating a slab of stainless steel which contains the above steel ingredients, setting the extraction temperature 1080 to 1190° C., and setting the coiling temperature after the end of hot rolling 500 to 700° C. After hot rolling, the method comprises annealing the hot rolled sheet, which can be omitted, cold rolling once or cold rolling twice or more which includes processing annealing, and finish annealing the steel sheet at 850 to 980° C. | 2013-01-17 |
20130017117 | BEARING STEELAANM Honjo; MinoruAACI OkayamaAACO JPAAGP Honjo; Minoru Okayama JPAANM Hase; KazukuniAACI OkayamaAACO JPAAGP Hase; Kazukuni Okayama JPAANM Kimura; HidetoAACI AichiAACO JPAAGP Kimura; Hideto Aichi JP - A bearing steel contains C: 0.56% by mass or more and 0.70% by mass or less, Si: 0.15% by mass or more and less than 0.50% by mass, Mn: 0.60% by mass or more and 1.50% by mass or less, Cr: 0.50% by mass or more and 1.10% by mass or less, P: 0.025% by mass or less, S: 0.025% by mass or less, Al: 0.005% by mass or more and 0.500% by mass or less, O: 0.0015% by mass or less, N: 0.0030% by mass or more and 0.015% by mass or less, and a remainder of Fe and incidental impurities. The bearing steel has a composition such that the eutectic carbide formation index Ec satisfies 02013-01-17 | |
20130017118 | ASYMMETRIC ROLLING DEVICE, ASYMMETRIC ROLLING METHOD AND ROLLED MATERIAL MANUFACTURED USING SAMEAANM Jeong; Hyo-TaeAACI GangneungAACO KRAAGP Jeong; Hyo-Tae Gangneung KRAANM Choe; Byung-HakAACI GangneungAACO KRAAGP Choe; Byung-Hak Gangneung KR - An asymmetric rolling method for rolling a rolling material by using at least one pair of working rolls comprises rolls rotating at the same linear velocity and having different diameters. An asymmetric rolling apparatus may comprise a first roll contacting a first surface of a rolling material, a second roll having a diameter different from that of the first roll and contacting a second surface of the rolling material opposite to the first surface, and a power providing unit for providing power to each of the first and second rolls to adjust a ratio between angular velocities of the first and second rolls. | 2013-01-17 |
20130017119 | DUAL CHAMBER BLOOD RESERVOIRAANM Silvestri; ClaudioAACI Quarantoli Mirandola (MO)AACO ITAAGP Silvestri; Claudio Quarantoli Mirandola (MO) ITAANM Tommasi; GabrieleAACI CavezzoAACO ITAAGP Tommasi; Gabriele Cavezzo IT - A blood reservoir may be used in combination with other elements such as a heart lung machine (HLM), oxygenator, heat exchanger, arterial filter and the like to form an extracorporeal blood circuit that may be employed in a procedure such as a bypass procedure. The blood reservoir may be configured to receive, filter and store blood from a number of sources including vent blood (from within the heart), venous blood (from a major vein), purge blood (from a sampling line) and cardiotomy or suction blood (from the surgical field). | 2013-01-17 |
20130017120 | CARBON MONOXIE (CO) MICROSIR SENSOR SYSTEM - A very small low cost apparatus and method are provided for determining concentration from a target gas by means optically monitoring one or more sensors that respond to carbon monoxide. The apparatus comprises a photon source optically coupled to the sensor and the photon intensity passing through the sensor is quantified by one or more photodiode(s) in a system, so that the photon flux is a function of at least one sensor's response to the target gas, e.g., transmits light through the sensor to the photodiode. The photocurrent from the photodiode is converted to a sensor reading value proportional to the optical characteristics of the sensors and is loaded into a microprocessor or other logic circuit. In the microprocessor, the sensor readings may be differentiated to determine the rate of change of the sensor readings and the total photons absorbed value may be used to calculate the CO concentration. | 2013-01-17 |
20130017121 | EXHAUST PURIFICATION SYSTEM OF INTERNAL COMBUSTION ENGINEAANM Bisaiji; YukiAACI Mishima-shiAACO JPAAGP Bisaiji; Yuki Mishima-shi JPAANM Yoshida; KoheiAACI Gotemba-shiAACO JPAAGP Yoshida; Kohei Gotemba-shi JPAANM Inoue; MikioAACI Susono-shiAACO JPAAGP Inoue; Mikio Susono-shi JPAANM Umemoto; KazuhiroAACI Ebina-shiAACO JPAAGP Umemoto; Kazuhiro Ebina-shi JP - In an internal combustion engine, inside of an engine exhaust passage, an upstream side air-fuel ratio sensor ( | 2013-01-17 |
20130017122 | METHODS AND SYSTEMS FOR MONITORING STERILIZATION STATUS - Methods and systems for monitoring sterilization status are provided. | 2013-01-17 |
20130017123 | METHOD OF FRESHENING AIR - Air freshener products and methods for freshening air are disclosed. In some embodiments, the air freshening product may include a container for storing an air freshening composition that may contain compressed gas such as compressed air, nitrogen, nitrous oxide, inert gases, or carbon dioxide. When the container is completely filled with propellant and air freshening composition, the air freshening composition may be released from the container at a flow rate of from about 0.8 grams/second to about 1.5 grams/second, wherein the mean particle size of the released spray droplets is from about 10 microns to about 100 microns. | 2013-01-17 |
20130017124 | POLYMERIZATION APPARATUS FOR DENTAL TECHNOLOGYAANM NOGUCHI; YukieAACI TokyoAACO JPAAGP NOGUCHI; Yukie Tokyo JP - Polymerization apparatus for dental technology, having a housing; a partition wall disposed in the housing so as to form a polymerization space where polymerization is carried out; a rotating table, which is arranged on a lower side of the polymerization space and on which the dental prosthesis is disposed directly or via other members; and a plurality of LED light sources which irradiate a light for the curing to a polymerization region, which is formed on the upper side of the rotating table and where the dental prosthesis can be disposed, wherein at least one of the plurality of LED light sources is disposed such that a light axis thereof is inclined obliquely upward to be directed toward the polymerization region. | 2013-01-17 |
20130017125 | SAMPLE PRESENTATION DEVICE FOR RADIATION-BASED ANALYTICAL EQUIPMENTAANM Claeys; Michael Christian MaximilianAACI Sea PointAACO ZAAAGP Claeys; Michael Christian Maximilian Sea Point ZAAANM Fischer; Nico FrederikAACI Cape TownAACO ZAAAGP Fischer; Nico Frederik Cape Town ZA - A sample presentation device for radiation-based analytical equipment is provided comprising a mounting base, a carrier carried by, and adjustable in position, typically in the vertical direction, relative to the mounting base, and an arm extending from the carrier and having at its opposite end a terminal member. Each of the carrier and terminal member has a coaxial connector for receiving two opposite end regions of a capillary tube that forms, in use, a reaction cell. A radiant heater, typically an infrared heater, is radially offset from the axis of the coaxial connectors for heating, in use, a capillary tube mounted by way of the coaxial connectors. The carrier and terminal member preferably have heaters associated therewith for heating the flow passages through them as and when necessary. The terminal member preferably has a passage generally coaxial with the connector for receiving a communications conductor carrying a temperature sensor at its end that is operatively located generally centrally within a capillary. | 2013-01-17 |
20130017126 | Cuvette-Based Apparatus for Blood Coagulation Measurement and Testing - An apparatus for measuring blood clotting time includes a blood clot detection instrument and a cuvette for use with the blood clot detection instrument. The cuvette includes a blood sample receptor-inlet; a channel arrangement including at least one test channel for performing a blood clotting time measurement, a sampling channel having at least one surface portion that is hydrophilic, communicating with the blood sample receptor-inlet and the at least one test channel, and a waste channel having at least one surface portion that is hydrophilic, communicating with the sampling channel; and a vent opening communicating with the sampling channel. The sampling channel, the vent opening and the waste channel, coact to automatically draw a requisite volume of a blood sample deposited at the blood receptor-inlet, into the sampling channel. | 2013-01-17 |
20130017127 | DISPENSING APPARATUSAANM TOKUMARU; TomoyoshiAACI Gunma-kenAACO JPAAGP TOKUMARU; Tomoyoshi Gunma-ken JP - A dispensing apparatus includes: a dish mounting portion having a mounting surface mounted with a dish having a bottom surface and a side surface surrounding the bottom surface; a syringe, arranged above the dish mounting portion, having a nozzle configured to discharge liquid toward an interior of the dish; and a first driving portion configured to change the syringe in direction with respect to a first axis as a center, wherein the first axis is orthogonal to a normal to the mounting surface of the dish mounting portion. | 2013-01-17 |
20130017128 | INTEGRATED ROBOTIC SAMPLE TRANSFER DEVICE - Embodiments include integrated robotic sample transfer devices and components thereof which are used for reliably and accurately transferring small samples of material from one registered position to another registered position. Such transfers of material may be carried out by a single pin tool or an array of pin tools of a pin tool head assembly of robotic sample transfer devices. Some embodiments also include automated cleaning of the pin tools used to transfer the sample material. Some embodiments are fully integrated units having internal fluid supply and waste tanks, vacuum source, fluid pumps, controllers and user interface devices. | 2013-01-17 |
20130017129 | PIPETTE MEMBER AND CELL ISOLATION INSTRUMENTAANM Shioyama; TakahiroAACI TokyoAACO JPAAGP Shioyama; Takahiro Tokyo JPAANM Suzuki; AkaneAACI TokyoAACO JPAAGP Suzuki; Akane Tokyo JP - A pipette member to be attachable to a container capable of accommodating a tissue and a liquid, is used for isolating cells from the tissue by stirring, and includes: a cylinder member which includes a first opening that is to be accommodated in the container, and a second opening that is to be connected to a cell isolation apparatus, and in which a passage for communicating the first opening with the second opening is defined; and a filter member which is disposed inside the cylinder member, and which separates the passage into a first part that includes the first opening, and a second part that includes the second opening. | 2013-01-17 |
20130017130 | BUFFY COAT SEPARATOR FLOAT SYSTEMS AND METHODS - Tube and float systems for separation and axial expansion of the buffy coat are provided. Generally, the systems include a flexible sample tube and a rigid separator float having a specific gravity intermediate that of red blood cells and plasma. The sample tube has an elongated sidewall having a first cross-sectional inner diameter. The float has a main body portion and one or more support members protruding from the main body portion to engage and support the sidewall of the sample tube. During centrifugation, the centrifugal force enlarges the diameter of the tube to permit density-based axial movement of the float in the tube. After centrifugation is ended, the tube sidewall returns to its first diameter, thereby capturing the float and trapping the buffy coat constituents in an annular volume. Several different systems for capturing and retrieving the buffy coat constituents are described. | 2013-01-17 |
20130017131 | SINGLE-USE CONTROLLED ENVIRONMENT MODULE - Disclosed herein is a single use, controlled environment manufacturing module in the form of a sterile sealed bag formed of a substantially flexible material, such that the bag can be inflated and deflated for transport and/or disposal. The flexible bag has one or more access ports and connectors to accommodate a variety of biochemical or pharmaceutical manufacturing processes to be carried out within the flexible bag. The interiors of one or more disclosed modules can be connected, forming a module train. | 2013-01-17 |
20130017132 | REAGENT RESERVOIR AND THERMOCONDUCTIVE ADAPTOR - A thermoconductive reservoir device and adaptor. | 2013-01-17 |
20130017133 | SYSTEMS AND METHODS FOR FLUID SAMPLE PROCESSING - A system for processing a fluid sample includes a tube and a piston. The tube has an open end and a closed end, and a volume defined therebetween. The volume is further defined by an interior surface of the tube. The tube is designed to receive a collection media holding the fluid sample. The piston has a first side and a second side, and is designed to be inserted into the tube via the open end of the tube. The piston is further designed to be translatable within the tube, and to compress the collection media between the closed end of the tube and the first side of the piston such that at least a portion of the fluid sample is removed from the collection media and driven to the second side of the piston. | 2013-01-17 |
20130017134 | BIODEGRADABLE STERILE SAMPLING BAGAANM Scally; May L.AACI St. Mathias sur RichelieuAACO CAAAGP Scally; May L. St. Mathias sur Richelieu CAAANM Parandoosh; ShorehAACI Mont Saint-HilaireAACO CAAAGP Parandoosh; Shoreh Mont Saint-Hilaire CAAANM Lafond; DanielleAACI Mont Saint-HilaireAACO CAAAGP Lafond; Danielle Mont Saint-Hilaire CA - A biodegradable sampling bag for containing samples or the like, comprises a flexible enclosure defining a chamber adapted to contain therein the sample, the flexible enclosure being made of a plastic material, which contains an additive that renders the flexible enclosure biodegradable when exposed for a sufficient period of time to microbial action. The additive is adapted to enable microorganisms to metabolize the molecular structure of said flexible enclosure. The additive is effective in altering the polymer chain of the plastic material to allow microbial action of a suitable environment to colonize in and around the plastic material, whereby microbes can then form a biofilm on a surface of the flexible enclosure and secrete acids which break down the entire polymer chain. The flexible enclosure, when exposed to microbial action, is adapted to withstand biodegradation for a given period of time, typically of at least three months. | 2013-01-17 |
20130017135 | GAS PURIFICATION USING PHOTOCATALYTIC VORTEX-SUSPENDED PARTICLESAANM Anderson; KraigAACI BurlingameAAST CAAACO USAAGP Anderson; Kraig Burlingame CA US - Embodiments of the technology disclosed herein include exemplary gas purifiers that use cyclonic separation and photocatalytic purification to oxidize contaminants in unpurified gas. One such gas purifier includes a vessel that defines a tapered cyclonic chamber. Unpurified gas enters the chamber and induces a gas vortex. Photocatalytic particles in the chamber become suspended in the vortex and mix with contaminants in the incoming gas. A light source activates the photocatalytic particles, which oxidize the contaminants to purify the gas. The purified gas exits via the wide of end of the chamber. Cyclonic action forces the photocatalytic particles out of the chamber's narrow end to a recycling conduit, which conveys the photocatalytic particles back into the chamber. | 2013-01-17 |
20130017136 | EXHAUST GAS CONTROL APPARATUS AND METHOD FOR INTERNAL COMBUSTION ENGINEAANM Hirota; ShinyaAACI Susono-shiAACO JPAAGP Hirota; Shinya Susono-shi JPAANM Yamashita; YoshinoriAACI Kakegawa-shiAACO JPAAGP Yamashita; Yoshinori Kakegawa-shi JP - A NOx selective reduction catalyst for reducing NOx by the ammonia adsorbed is disposed in an engine exhaust gas passage. As states of adsorption of ammonia by the catalyst, there are a first adsorption state of ammonia that occurs when the ammonia is adsorbed during low temperature and a second adsorption state of ammonia that occurs when the ammonia is adsorbed or has already been adsorbed during high temperature. The amount of adsorbed ammonia in the first state is restricted to control concentration of the ammonia that is in the first state and desorbed when the temperature of the catalyst increases so as to be not higher than an allowable concentration, and that in the second state is restricted to control concentration of the ammonia that is in the second state and desorbed when the temperature of the catalyst increases so as to be not higher than an allowable concentration. | 2013-01-17 |
20130017137 | LANTHANUM HEXABORIDE SINTERED BODY, TARGET AND LANTHANUM HEXABORIDE FILM EACH COMPRISING SAME, AND PROCESS FOR PRODUCTION OF THE SINTERED BODYAANM Takahashi; KentaroAACI ChibaAACO JPAAGP Takahashi; Kentaro Chiba JPAANM Andou; KazutoAACI ChibaAACO JPAAGP Andou; Kazuto Chiba JP - Disclosed are: a lanthanum hexaboride sintered body which contains lanthanum hexaboride as the main component, has an element nitrogen content of 0.1 to 3 mass % inclusive, contains an impurity composed of element carbon and/or at least two elements selected from La, C, O and B at a content of 0.3 vol % or less, and has a relative density of 88% or more; and a target comprising the lanthanum hexaboride sintered body. An LaB | 2013-01-17 |
20130017138 | METHOD FOR PRODUCING HEXACHLORODISILANEAANM Auner; NorbertAACI GlashuettenAACO DEAAGP Auner; Norbert Glashuetten DEAANM Bauch; ChristianAACI MuldensteinAACO DEAAGP Bauch; Christian Muldenstein DEAANM Holl; SvenAACI GueckingenAACO DEAAGP Holl; Sven Gueckingen DEAANM Deltschew; RumenAACI LeipzigAACO DEAAGP Deltschew; Rumen Leipzig DEAANM Mohsseni; JavadAACI Bitterfeld-WolfenAACO DEAAGP Mohsseni; Javad Bitterfeld-Wolfen DEAANM Lippold; GerdAACI LeipzigAACO DEAAGP Lippold; Gerd Leipzig DEAANM Gebel; ThoralfAACI DresdenAACO DEAAGP Gebel; Thoralf Dresden DE - A method produces hexachlorodisilane. Hexachlorodisilane is obtained by oxidative splitting of the chlorinated polysilane of the empirical formula SiClx (x=0,2-0,8) using chlorine gas. The hexachlorodisilane is selectively obtained with a high yield. | 2013-01-17 |
20130017139 | Methods and Systems For Monitoring and Controlling Silicon Rod Temperature - Systems and methods are disclosed for monitoring and controlling silicon rod temperature. One example is a method of monitoring a surface temperature of at least one silicon rod in a chemical vapor deposition (CVD) reactor during a CVD process. The method includes capturing an image of an interior of the CVD reactor. The image includes a silicon rod. The image is scanned to identify a left edge of the silicon rod and a right edge of the silicon rod. A target area is identified midway between the left edge and the right edge. A temperature of the silicon rod in the target area is determined. | 2013-01-17 |
20130017140 | METHOD FOR PROCESSING SILICON POWDER TO OBTAIN SILICON CRYSTALS - Embodiments of the present invention relate to a process for obtaining silicon crystals from silicon. The method includes contacting silicon powder with a solvent metal to provide a mixture containing silicon, melting the silicon under submersion to provide a first molten liquid, contacting the first molten liquid with a first gas to provide dross and a second molten liquid, separating the dross and the second molten liquid, cooling the second molten liquid to form first silicon crystals and a first mother liquid and separating the first silicon crystals and the first mother liquid. | 2013-01-17 |
20130017141 | APPLICATION OF POROUS STRUCTURED ORGANIC FILMS FOR GAS STORAGEAANM COTE; Adrien P.AACI ClarksonAACO CAAAGP COTE; Adrien P. Clarkson CAAANM HEUFT; Matthew A.AACI OakvilleAACO CAAAGP HEUFT; Matthew A. Oakville CA - A porous structured organic film for storing gaseous a gaseous entity and method for storing gaseous entities in a porous structured organic film, the porous structured organic film including a plurality of segments and a plurality of linkers arranged as a covalent organic framework, wherein at a macroscopic level the covalent organic framework is a film and contains a plurality of sites accessible to one or more gaseous entity. | 2013-01-17 |
20130017142 | APPARATUS FOR PRODUCING NANOCARBON MATERIAL AND METHOD FOR PRODUCING NANOCARBON MATERIALAANM Noda; SuguruAACI Bunkyo-kuAACO JPAAGP Noda; Suguru Bunkyo-ku JPAANM Osawa; ToshioAACI Bunkyo-kuAACO JPAAGP Osawa; Toshio Bunkyo-ku JPAANM Kim; Dong YoungAACI Bunkyo-kuAACO JPAAGP Kim; Dong Young Bunkyo-ku JPAANM Haba; EisukeAACI Tsukuba-shiAACO JPAAGP Haba; Eisuke Tsukuba-shi JPAANM Ueda; ShunsukeAACI Tsukuba-shiAACO JPAAGP Ueda; Shunsuke Tsukuba-shi JP - The present invention provides a carbon nanomaterial production apparatus | 2013-01-17 |
20130017143 | PHOSPHOR AND MANUFACTURING METHODAANM ITO; MichimasaAACI AichiAACO JPAAGP ITO; Michimasa Aichi JPAANM MATSUSHIMA; YutaAACI Yonezawa-shiAACO JPAAGP MATSUSHIMA; Yuta Yonezawa-shi JPAANM HIRO-OKA; MasahiroAACI Yonezawa-shiAACO JPAAGP HIRO-OKA; Masahiro Yonezawa-shi JP - An alkali-earth vanadate compound functioning as a phosphor is a reaction product of vanadium oxide and an alkaline-earth metal or salt thereof. | 2013-01-17 |
20130017144 | METHOD AND DEVICE FOR PROCESSING SOUR GAS RICH IN CARBON DIOXIDE IN A CLAUS PROCESSAANM Menzel; JohannesAACI WaltropAACO DEAAGP Menzel; Johannes Waltrop DE - A method and apparatus for processing a sour gas rich in carbon dioxide in a Claus process, so sulfur compounds are removed by a selective solvent in a gas scrubbing process. Sulfur components and carbon dioxide, are separated into at least two sour gas fractions, wherein at least one sour gas fraction having a higher content of sulfur components is obtained, wherein the fraction having the highest hydrogen sulfide content is introduced in the thermal reaction stage of the Claus furnace with a gas containing oxygen by means of a burner. The sulfur is converted to sulfur dioxide in the thermal reaction stage of the Claus furnace and exhaust gases are discharged into the closed Claus reaction chamber behind the burner. The remaining sour gas fractions stripped of sulfur components are fed to the Claus reaction chamber and are mixed with the combustion gases leaving the burner. | 2013-01-17 |
20130017145 | METHODS FOR SYNTHESIZING METAL OXIDE NANOWIRESAANM Sunkara; Mahendra KumarAACI LouisvilleAAST KYAACO USAAGP Sunkara; Mahendra Kumar Louisville KY USAANM Kumar; VivekanandAACI LouisvilleAAST KYAACO USAAGP Kumar; Vivekanand Louisville KY USAANM Kim; Jeong H.AACI LouisvilleAAST KYAACO USAAGP Kim; Jeong H. Louisville KY USAANM Clark; Ezra LeeAACI LouisvilleAAST KYAACO USAAGP Clark; Ezra Lee Louisville KY US - A method of synthesizing a metal oxide nanowire includes the steps of: combining an amount of a transition metal or a transition metal oxide with an amount of an alkali metal compound to produce a mixture; activating a plasma discharge reactor to create a plasma discharge; exposing the mixture to the plasma discharge for a first predetermined time period such that transition metal oxide nanowires are formed; contacting the transition metal oxide nanowires with an acid solution such that an alkali metal ion is exchanged for a hydrogen ion on each of the transition metal oxide nanowires; and exposing the transition metal oxide nanowires to the plasma discharge for a second predetermined time period to thermally anneal the transition metal oxide nanowires. Transition metal oxide nanowires produced using the synthesis methods described herein are also provided. | 2013-01-17 |
20130017146 | METHOD FOR PRODUCING HYDROGEN WITH REDUCED CO2 EMISSIONSAANM Darde; ArthurAACI ParisAACO FRAAGP Darde; Arthur Paris FRAANM Valentin; SoleneAACI MeudonAACO FRAAGP Valentin; Solene Meudon FRAANM Court; PhilippeAACI VincennesAACO FRAAGP Court; Philippe Vincennes FRAANM Tranier; Jean-PierreAACI L'Hay-Les-RosesAACO FRAAGP Tranier; Jean-Pierre L'Hay-Les-Roses FRAANM Traversac; XavierAACI ParisAACO FRAAGP Traversac; Xavier Paris FRAANM Terrien; PaulAACI BaltimoreAAST MDAACO USAAGP Terrien; Paul Baltimore MD US - The present invention relates to a method for producing hydrogen, with reduced carbon dioxide emissions, from a hydrocarbon mixture. In said method, the hydrocarbon mixture is reformed so as to produce a synthetic gas that is cooled, then treated in a shift reactor so as to be enriched with H2 and CO2. Optionally dried, said mixture is treated in a PSA hydrogen purification unit in order to produce hydrogen. The residue is treated by means of partial condensation with a view to capturing CO4 before said residue is sent as fuel to reforming. | 2013-01-17 |
20130017147 | TARGETING AGENT FOR TUMOR SITEAANM Ogiwara; KazutakaAACI Ashigarakami-gunAACO JPAAGP Ogiwara; Kazutaka Ashigarakami-gun JPAANM Ohno; MakotoAACI Ashigarakami-gunAACO JPAAGP Ohno; Makoto Ashigarakami-gun JPAANM Kojima; MasayoshiAACI Ashigarakami-gunAACO JPAAGP Kojima; Masayoshi Ashigarakami-gun JPAANM Kawakami; MasayukiAACI Ashigarakami-gunAACO JPAAGP Kawakami; Masayuki Ashigarakami-gun JPAANM Kakinuma; ChihayaAACI Ashigarakami-gunAACO JPAAGP Kakinuma; Chihaya Ashigarakami-gun JPAANM Sasaki; TasukuAACI Ashigarakami-gunAACO JPAAGP Sasaki; Tasuku Ashigarakami-gun JPAANM Takada; KiyohitoAACI Ashigarakami-gunAACO JPAAGP Takada; Kiyohito Ashigarakami-gun JP - It is an object of the present invention to provide a targeting agent, which enables the delivery of a drug to tumor sites or the imaging of tumor sites by utilizing its effect of accumulating to such tumor sites. The present invention provides a targeting agent for tumor site, which comprises a hydrophilic polymer-modified carrier coated with a gelatin-like protein that has repeats of a sequence represented by Gly-X—Y characteristic to collagen and has two or more sequences of cell adhesion signals in a single molecule wherein X and Y each independently represent an amino acid and a plurality of Gly-X—Y sequences may be the same or different. | 2013-01-17 |
20130017148 | SYSTEMS FOR PRODUCING MULTILAYERED PARTICLES, FIBERS AND SPRAYS AND METHODS FOR ADMINISTERING THE SAME - Capsules and particles with at least one encapsulated and/or entrapped agent, such as therapeutic agent, imaging agents, and other constituents may be produced by electrohydrodynamic processes. More particularly, the agent encapsulated in a vehicle, capsule, particle, vector, or carrier may maximize treatment and/or imaging of malignant cancers while minimizing the adverse effects of treatment and/or imaging. | 2013-01-17 |
20130017149 | PHARMACEUTICAL COMPOUNDS - Condensed tricyclic compounds having a condensed structure containing one phenyl and one pyrazole ring linked with each other by a central ring comprising from five to eight atoms, having affinity for the CB1 and/or CB2 receptors, with central nervous system and/or peripheral activity, of formula (I): | 2013-01-17 |
20130017150 | METHODS FOR PREVENTION AND TREATMENT OF ACUTE RENAL INJURY - The disclosure relates to a method for protecting a kidney from renal injury. For example, acute renal injury may be associated with decreased or blocked blood flow in the subject's kidney or exposure to a nephrotoxic agent, such as a radiocontrast dye. The methods include administering to the subject an effective amount of an aromatic-cationic peptide to a subject in need thereof. | 2013-01-17 |
20130017151 | SUBSETS OF ANTIGEN-PRESENTING CELLS (APCs) IN THE HUMAN VAGINA AND THEIR DISTINCT FUNCTIONS - Compositions and methods for generating dendritic cell (DC)-targeting vaccines against vaginal infections, including but not limited to sexually transmitted diseases, are disclosed herein. The present invention reports the isolation of at least four major subsets of myeloid-originated antigen-presenting cells (APCs) that possess distinct phenotypes and functions in directing immune responses, namely, Langerhans cells (LCs: E-cadherin | 2013-01-17 |
20130017152 | METHOD FOR THE TREATMENT OF MULTIPLE SCLEROSIS - A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of an IL-21 receptor antagonist, wherein the subject has failed to respond treatment with beta interferon, thereby treating the subject. | 2013-01-17 |
20130017153 | UNIT DOSAGE OF APADENOSON - The present invention provides a unit dosage of Apadenoson, a pharmacological stress agent, and use of the same as a pharmacologic agent for myocardial perfusion imaging. | 2013-01-17 |
20130017154 | Uniform Fluorescent Microsphere with Hydrophobic Surfaces - Fluorescent microspheres for the measurement of blood flow are provided. The microspheres are substantially uniform in diameter and have a hydrophobic surface, which allows them to circulate more freely throughout bloodstream, while reducing immunogenicity, particle aggregation and bioaccumulation. The hydrophobic surface on each microsphere is generally comprised of polymeric material having a limited surface charge. | 2013-01-17 |
20130017155 | DUAL CT/MRI NANOPARTICLE CONTRAST AGENT - The invention relates to a new tungsten-iron-Ferritin nanoparticle and uses thereof in imaging. | 2013-01-17 |
20130017156 | CEFDINIR AND CEFIXIME FORMULATIONS AND USES THEREOF - The invention features pharmaceutically acceptable salts of cefdinir, including primary, secondary, and tertiary amine salts of cefdinir, and preparation methods, and pharmaceutical compositions including cefdinir. The invention also features water dispersible pharmaceutical dosage forms including cefdinir as active agent and methods for preparing the dosages. The invention also features tablet forms of cefixime characterized in that the tablets are in effervescent form. The invention also features the process for preparing effervescent tablet forms with cefdinir as active agents and pharmaceutical formulations obtained by the process. | 2013-01-17 |
20130017157 | HAIR STYLING COMPOSITIONAANM Grit; MustafaAACI GernsheimAACO DEAAGP Grit; Mustafa Gernsheim DEAANM Wood; JonathanAACI WeinheimAACO DEAAGP Wood; Jonathan Weinheim DE - The present invention is related to a hair styling composition for keratin fibres especially for hair comprising at least one film forming polymer and at least one dipeptide. | 2013-01-17 |
20130017158 | Oral Care Compositions Comprising Phytic AcidAANM HOKE II; Steven HamiltonAACI West ChesterAAST OHAACO USAAGP HOKE II; Steven Hamilton West Chester OH USAANM STRAND; RossAACI BeijingAACO CNAAGP STRAND; Ross Beijing CNAANM WANG; XiaoliAACI BeijingAACO CNAAGP WANG; Xiaoli Beijing CNAANM ZHANG; YiqunAACI BeijingAACO CNAAGP ZHANG; Yiqun Beijing CN - An oral care composition comprising a stannous ion source and/or a zinc ion source; a phytic acid or a phytic acid salt or mixtures thereof; characterised in that the phytic acid or phytic acid salt has an average IPn of greater than 5.2. In a composition which comprises stannous, there is a decrease in soluble stannous whilst maintaining an equivalent efficacy to a composition comprising a higher level of soluble stannous and efficacy is observed for avoiding stain and astringency problems. When zinc ions are present, it has been surprisingly found that a decrease in soluble zinc can provide an equivalent antimicrobial efficacy to a composition comprising a greater level of soluble zinc. | 2013-01-17 |
20130017159 | NOVEL COMPOSITIONAANM Lippert; FrankAACI WeybridgeAACO GBAAGP Lippert; Frank Weybridge GBAANM Lucas; Robert AnthonyAACI WeybridgeAACO GBAAGP Lucas; Robert Anthony Weybridge GB - A dentifrice composition providing superior shine and polish, low RDA and effective whitening comprising a calcined aluminium oxide polishing agent, a water soluble condensed phosphate such as an alkali metal phosphate salt and an orally acceptable carrier or excipient is described. The composition is free of a silica abrasive. | 2013-01-17 |
20130017160 | THICKENING ADDITIVE COMPOSITIONS - A thickening additive composition comprising: (A) a substantially anhydrous solvent system; and (B) a thickening agent, wherein the thickening agent comprises a strongly swellable, lightly to moderately crosslinked polyvinylpyrrolidone. Personal care compositions containing the thickening additive composition are also described. | 2013-01-17 |
20130017161 | Cosmetic Compositions with Silicone Resin Polymers - A cosmetic composition containing a silicone resin polymer comprised of M units in combination with Q or T units or both, wherein the number of M units is greater than the number of Q units or T units or combination thereof, and a method for improving the finish of a cosmetic composition. | 2013-01-17 |
20130017162 | COSMETIC COMPOSITION, COSMETIC TREATMENT METHOD, KIT, AND COMPOUND - The invention relates to a cosmetic composition, especially a hair composition, and to a method for the cosmetic treatment of keratin materials, especially of the hair, employing compounds of formula: | 2013-01-17 |
20130017163 | HALOGENATED PHENOLS FOR DIAGNOSTICS, ANTIOXIDANT PROTECTION AND DRUG DELIVERY - The present invention provides compositions and methods of their administration for the protection of cells and tissues from damage caused by FROS in the body of an individual. Compositions comprising halogenated phenol compounds are provided that scavenge or consume FROS in the body. These FROS scavenging compounds may not only protect cells and tissues from damage, but also treat disease and/or alleviate the symptoms of disease associated with high FROS levels. Sunscreen compositions comprising FROS-scavenging compounds of the present invention are further provided to reduce the damaging effects of sunlight on the skin of an individual. | 2013-01-17 |
20130017164 | COSMETIC DERMATOLOGICAL COMPOSITION, COSMETIC TREATMENT METHOD, AND HYALURONIC ACID DERIVATIVE - The invention relates to a cosmetic or dermatological composition comprising a hyaluronic acid derivative which comprises ureidopyrimidone units, to the said derivatives and to a cosmetic treatment method using them. | 2013-01-17 |
20130017165 | Pure Chlorine Dioxide Solution, and Gel-Like Composition and Foaming Composition Each Comprising the Same - A pure chlorine dioxide solution includes a chlorine dioxide gas dissolved therein, a chlorite, and a pH adjuster which is an acid or a salt thereof having a buffering property whose pH is 2.5 to 6.8 as a 5% aqueous solution at 25° C. | 2013-01-17 |
20130017166 | Protein-Poly(2-oxazoline) Conjugates for Enhanced Cellular Delivery and Transport Across Biological Barriers - The present invention provides polymer conjugates and methods of use thereof. | 2013-01-17 |
20130017167 | HYDROPHOBIC BLOCK CONJUGATED THERAPEUTIC AGENTS - Provided herein are polymers having a therapeutic agent covalently coupled to a hydrophobic block thereof, as well as micelles and therapeutic compositions thereof. | 2013-01-17 |
20130017168 | METHODS FOR ENHANCING THE EFFICACY OF IL-2 MEDIATED IMMUNE RESPONSES - Methods directed to enhancing the effectiveness of IL-2 in stimulating the immune system is disclosed. According to one method, an antagonist directed against the CD25 subunit of the high-affinity IL-2 receptor complex is administered in conjunction with IL-2. The CD25 antagonist may be an anti-CD25 antibody. According to another method, an anti-IL-2 antibody is administered in conjunction with IL-2. In another method, a mutant IL-2 with diminished ability to bind the CD25 subunit of the high-affinity IL-2 receptor complex is administered. In another method, an CD4 antagonist is administered in conjunction with IL-2 in order to stimulate the immune system. | 2013-01-17 |
20130017169 | MULTIMERIC FORMS OF THERAPEUTIC PROTEINS AND USES THEREOF - Multimeric protein structures are disclosed herein, as well a process for preparing same, and methods employing same for treating various diseases or disorders. The multimeric protein structures comprise at least two monomers of a therapeutic protein, including a TNF-alpha, a luteinizing hormone, an immunoglobin, a TNF-alpha receptor, a CTLA-4, a urate oxidase, a VEGF, a PDGF, a VEGF receptor, a PDGF receptor, an interleukin-17, and/or fragments thereof, the monomers being covalently linked to one another via a linking moiety. The multimeric protein structures exhibit improved performance as compared to the corresponding native proteins, including a longer lasting activity in vivo. | 2013-01-17 |
20130017170 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS - Compounds represented by formula (Ia) or (Ib) and wherein R and R | 2013-01-17 |
20130017171 | METHODS AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS - A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1′, 2′ or 3′-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided. | 2013-01-17 |
20130017172 | Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells With a Virus - The present invention relates to a method of increasing the sensitivity of neoplastic cells to chemotherapeutic agents by using a virus, a method of treating proliferative disorders with a virus and chemotherapeutic agents, and a method for preventing a neoplasm from developing drug resistance to chemotherapeutic agents. The virus is preferably a reovirus. | 2013-01-17 |
20130017173 | NOVEL COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE AND AIRWAY INFLAMMATION - Provided are compositions and methods for treating inflammation due to an immune response. Non-limiting example compositions include class-2 SPATE proteins that are capable of cleaving proteins involved in an inflammatory immune response in a patient. Example compositions include at least one mucin-cleaving class-2 SPATE protein. Further example compositions include protein involved in intestinal colonization (Pic). Non-limiting example methods include methods of decreasing inflammation in a patient having inflammation and methods of perturbing immune response in a patient having a disease or condition in which an active immune response is attributable to a cause of the disease or condition, by administering to the patient a composition including at least one class-2 SPATE protein capable of cleaving proteins involved in an inflammatory immune response. | 2013-01-17 |
20130017174 | COMPOSITIONS AND METHODS FOR INCREASING HEALTH AND REDUCING PATHOGENIC BACTERIA IN ANIMALS - Probiotic compositions comprising a bacterium that is capable of producing nitric oxide and a substrate of nitric oxide synthase are provided. Also provided are methods of improving the gastrointestinal health of a subject by orally administering a bacterium capable of producing nitric oxide and orally administering a substrate of nitric oxide synthase. Methods of reducing the inflammatory immune response after treatment with a probiotic and methods of reducing horizontal transmission of pathogenic bacteria within groups of animals are also provided. | 2013-01-17 |
20130017175 | ACTIVATED MESENCHYMAL STEM CELLS FOR WOUND HEALING AND IMPAIRED TISSUE REGENERATION - Inflammatory cytokines e.g. IFN-γ, serve as initiating stimuli for mesenchymal stem cell (MSC) immunosuppresive activity in vivo. Other inflammatory cytokines, such as TNF alpha, the molecule hemoxygenase I, and TLR ligation of MSC, may also provide such a response. Activated MSC's promote tissue regeneration in conditions such as aging, where regeneration is impaired. Wound healing in aged mammals was enhanced by restoring tensile strength to the levels of younger mammals. Activated MSCs were useful in treating wounds in diabetic primates. | 2013-01-17 |
20130017176 | COMPOSITIONS COMPRISING CARDIAC STEM CELLS OVEREXPRESSING SPECIFIC MICRORNAS AND METHODS OF THEIR USE IN REPAIRING DAMAGED MYOCARDIUM - The invention provides compositions comprising modified stem cells containing a transgene that affects the expression of at least one gene that inhibits or promotes cardiomyogenesis. In particular, the invention discloses compositions comprising cardiac stem cells, wherein said cardiac stem cells comprise a transgene encoding a microRNA. The compositions of the invention find use in the treatment of cardiovascular disorders, such as myocardial infarction. Methods of repairing damaged myocardium in a subject using the modified stem cells are also disclosed. | 2013-01-17 |
20130017177 | PHOTO-CROSSLINKED GELLAN GUM-BASED HYDROGELS: PREPARATION METHODS AND USES THEREOFAANM Da Silva Correia; Joana CatarinaAACI BragaAACO PTAAGP Da Silva Correia; Joana Catarina Braga PTAANM Antunes De Oliveira; Joaquin MiguelAACI Ponte GMRAACO PTAAGP Antunes De Oliveira; Joaquin Miguel Ponte GMR PTAANM Teixeira De Oliveira; Joao ManuelAACI MatosinhosAACO PTAAGP Teixeira De Oliveira; Joao Manuel Matosinhos PTAANM Amandi Romero De Sousa; Rui PedroAACI MatosinhosAACO PTAAGP Amandi Romero De Sousa; Rui Pedro Matosinhos PTAANM Goncalves Dos Reis; Ruic LuisAACI PortoAACO PTAAGP Goncalves Dos Reis; Ruic Luis Porto PT - This invention refers to photo-crosslinked hydrogel materials based in gellan gum suitable for tissue engineering and regenerative medicine applications or as drug delivery systems. Formulations of gellan gum with different degrees of acylation serve as precursor material for insertion of a polymerizable moiety. The materials are capable of free radical polymerization with a photo-initiator at mild temperatures and exposure to ultraviolet light, enabling control of reticulation and withstanding the encapsulation of human and animal cells and/or drugs, and any combination thereof. The physicochemical and biological properties can be adjusted by combining different formulations of gellan gum and reaction conditions. The matrix can be used either as an acellular or cellular system, dispensed manually or automatically by injection and crosslinked directly at the site of application, and can be processed using manual or automated systems in different types of scaffolds, such as hydrogels, fibres, | 2013-01-17 |
20130017178 | PREPARATION CREATED FROM AN IN VITRO CULTURE OF DEDIFFERENTIATED, NON-ELICITED CELLS OF THE ARGANIA TREE, USE THEREOF FOR TREATING SKIN AGEING, INFLAMMATION AND SCARRING, AND PRODUCTION THEREOFAANM Steward; NicolasAACI Pins-JustaretAACO FRAAGP Steward; Nicolas Pins-Justaret FRAANM Mandeau; AnneAACI ToulouseAACO FRAAGP Mandeau; Anne Toulouse FRAANM Castex-Rizzi; NathalieAACI ColomiersAACO FRAAGP Castex-Rizzi; Nathalie Colomiers FR - The invention relates to a preparation created from an in vitro culture of dedifferentiated, non-elicited cells of the Argania tree. | 2013-01-17 |
20130017179 | Lineage-Restricted Neuronal Precursors - A cell population has been identified and isolated that can differentiate into multiple neuronal phenotypes, but cannot differentiate into glial phenotypes. This mammalian CNS neuron-restricted cell expresses highly polysialated or embryonic neural cell adhesion molecule (E-NCAM) and is morphologically distinct from neuroepithelial stem cells (NEP cells) and spinal glial progenitors derived from embryonic day 10.5 spinal cord. Methods for isolating these cells and uses thereof are also disclosed. | 2013-01-17 |
20130017180 | PLATELET RICH PLASMA FORMULATIONS - Compositions for platelet rich plasma (PRP) and neutrophil-depleted PRP are provided. Methods for treating ischemia damaged tissues by delivering a PRP composition, in some embodiments a neutrophil-depleted PRP composition to the damaged tissue are provided. In some variations, the compositions may be useful to treat ischemic heart disease and repair damaged cardiovascular tissue following acute myocardial infarction including congestive heart failure. In some variations, the compositions may be useful to reduce cardiac apoptosis after a heart attack. | 2013-01-17 |
20130017181 | LIPID-METABOLISM-AMELIORATING AGENT - Methods for lowering serum triglycerides use pharmaceutical agents and food products that have no side effects, are easy to ingest continuously, and have a serum triglyceride-lowering effect are provided. The pharmaceutical agents and food products are lipid metabolism-ameliorating agents and serum triglyceride-lowering agents, which include as an active ingredient a culture of a bacterium belonging to the genus | 2013-01-17 |
20130017182 | MULTI-CRITERIA OPTIMIZED DIETARY SUPPLEMENT FORMULATIONS - Dietary micronutrient supplement formulations for specific ages, gender, special requirements and health conditions comprising, vitamins, minerals, fish and plant oils, amino acids, enzymes, phytochemicals, herb and fruit extracts and other natural compounds grouped into morning, mid-day and evening formulas based on their synergism and antagonism with each other, their interactions with ingredients in the food consumed during each meal and their bioavailability. The dietary micronutrient formulations are optimized to meet the Recommended Daily Allowances (RDA) and Adequate Intake (AI) standards for each segment of the population with larger amounts of nutrients used in condition-specific formulas. | 2013-01-17 |
20130017183 | Compositions containing non-polar compounds - Provided herein are compositions and methods for preparing foods and beverages that contain additives. Additives include nutraceuticals, pharmaceuticals, and supplements, such as essential fatty acids, including omega-3 fatty acids, omega-6 fatty acids, conjugated fatty acids, and other fatty acids; phytochemicals, including phytosterols; other oils; and coenzymes, including Coenzyme Q10, and other oil-based additives. | 2013-01-17 |
20130017184 | Stabilised solid compositions of factor VII polypeptides - The invention relates to chemically as well as physically stable compositions comprising Factor VII or a Factor VII-related polypeptide such that these compositions can be stored, handled and used at room temperature. | 2013-01-17 |
20130017185 | Thermostable Phytase VariantsAANM De Maria; LeonardoAACI FrederiksbergAACO DKAAGP De Maria; Leonardo Frederiksberg DKAANM Skov; Lars KobberoeeAACI BagsvaerdAACO DKAAGP Skov; Lars Kobberoee Bagsvaerd DKAANM Skjoet; MichaelAACI RoskildeAACO DKAAGP Skjoet; Michael Roskilde DK - The present invention relates to a phytase which has at least 70% identity to a phytase derived from | 2013-01-17 |
20130017186 | ADHERENT ANTIMICROBIAL BARRIER AND SANITIZING AGENT - Provided are viscous and adherent food-safe antimicrobial compositions, and methods for using same in the immediate and residual decontamination of microbial-contaminated substrate surfaces, in reducing or precluding cutting implement-mediated transfer of surface contamination during cutting operations in the food industry, and for reducing or preventing transfer of contamination from contaminated surfaces in the food and pharmaceutical industries. Adherent antimicrobial protective layers are formed on substrate surfaces (e.g., processing equipment and utensils), providing a barrier (e.g., chemical and/or physical) to the passage or transport of microbial contamination between and among surfaces. The adherent formulations confer residual decontaminating activity, providing for prolonged killing of associated microbial contamination, are preferably formulated and applied as a gel, syrup or foam, and preferably comprise materials that are ‘generally-regarded-as-safe’ (GRAS) in food products, obviating post-treatment removal prior to consumption. Preferably, the inventive formulations are heated to a temperature ≧about 80° C. prior to application. | 2013-01-17 |
20130017187 | PHARMACOLOGICAL COMPOSITION WHEREBY STATIN AND COQ10 COMPOUNDS ARE ENHANCEDAANM Pyo; Young-HeeAACI Gwangju-siAACO KRAAGP Pyo; Young-Hee Gwangju-si KR - Disclosed is a pharmaceutical natural composition containing both statin compounds (mevinolin and mevinolinic acid) serving as cholesterol biosynthesis inhibitors and coenzyme Q (ubiquinone-10: CoQ10 and ubiquinone-9: CoQ9) compounds which are substances that inhibit factors causing complications such as myalgia involved in long-term use of the statin, prepared using | 2013-01-17 |
20130017188 | MODULATION OF SGK1 EXPRESSION IN TH17 CELLS TO MODULATE TH17-MEDIATED IMMUNE RESPONSES - The inventors have made the surprising discovery that SGK1, a serine/threonine kinase previously described as being involved in regulation of cellular sodium homeostasis, has a novel and unexpected function in the differentiation and function of a specific subset of CD4 T cells, the TH17 lineage. Described herein are methods and compositions for modulation of TH17 cell differentiation, proliferation, and/or function that rely upon modulating the activity or expression of SGK1. Such methods and compositions are useful in the treatment of disorders including autoimmune diseases, chronic inflammatory conditions, infectious diseases, and cancer. | 2013-01-17 |
20130017189 | Functionalised Triblock Copolymers and Compositions Containing Such PolymersAANM Pierre; Sebastien JeromeAACI MaastrichtAACO NLAAGP Pierre; Sebastien Jerome Maastricht NLAANM De Leeuw; MikeAACI MaastrichtAACO NLAAGP De Leeuw; Mike Maastricht NL - Amphiphilic triblock copolymers B-A-B, wherein A is a linear poly(ethylene glycol) block, having a number average molecular weight (M | 2013-01-17 |
20130017190 | TREATMENT OF INFLAMMATORY DISEASES - The present invention relates generally to the field of inflammatory diseases of the peripheral nervous system. More particularly, it concerns methods for treating inflammatory diseases of the peripheral nervous system by modulating sphingosine-1-phosphate receptor activity. In one embodiment, the present invention provides a method of treating a subject with chronic inflammatory demyelinating polyneuropathy (CIDP) or other autoimmune neuropathies comprising administering to the subject an effective amount of FTY720. | 2013-01-17 |
20130017191 | IMMUNOGLOBULIN PREPARATION AND STORAGE SYSTEM FOR AN IMMUNOGLOBULIN PREPARATION - The present invention relates to an immunoglobulin preparation comprising immunoglobulin in a mass-volume percentage of at least 4%, wherein the concentration of oxygen dissolved in the preparation at room temperature is less than 40 μmol/l. | 2013-01-17 |
20130017192 | Diagnosis and Treatment of Autoantibody-Mediated Heart DiseaseAANM Lipes; Myra A.AACI BrooklineAAST MAAACO USAAGP Lipes; Myra A. Brookline MA USAANM Cornivelli; LizbethAACI MedfordAAST MAAACO USAAGP Cornivelli; Lizbeth Medford MA US - Provided herein are, inter alia, methods of diagnosing and treating autoimmune cardiomyopathy in subjects, based upon the detection of IgG4 autoantibodies to cardiac troponin I (cTnI). | 2013-01-17 |
20130017193 | ANTIBODY FORMULATIONS - Formulations of VLA-4 binding antibody are described. | 2013-01-17 |
20130017194 | FAK INHIBITORS - A compound of the formula (I): | 2013-01-17 |
20130017195 | ANTI-FOLATE RECEPTOR ALPHA ANTIBODIES AND USES THEREOF - Described herein are antibodies, and antigen-binding fragments thereof, that are specific for folate receptor alpha, related polynucleotides, expression vectors, and cells that express the described antibodies. Also provided are methods of using the described antibodies, and antigen-binding fragments thereof, and related kits. Provided herein are also methods for diagnosing cancers, such as breast cancer, thyroid cancer, colorectal cancer, endometrial cancer, fallopian tube cancer, ovarian cancer, or lung cancer, using the described antibodies, and antigen-binding fragments thereof. The methods involve determining the amount of folate receptor alpha in a sample derived from a subject and comparing this level with the level of folate receptor alpha in a control sample or reference sample. | 2013-01-17 |
20130017196 | SUBSTITUTED IMIDAZOLE DERIVATIVES - The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula: | 2013-01-17 |
20130017197 | STABILIZED ANTIBODY PREPARATIONS AND USES THEREOF - The present invention is directed to stabilized intact antibody formulations, related methods and uses thereof. In particular, the invention relates to a method of stabilizing an intact antibody in a liquid carrier. | 2013-01-17 |
20130017198 | MANIPULATION OF CALCIUM CHANNELS TO REGULATE AFTER-DEPOLARIZATION EVENTS IN CARDIAC MYOCYTES - A novel mechanism by which after-depolarization occurs in cardiac myocytes has been discovered, involving calcium influx through the arachidonate-regulated calcium channel (ARCC) and the store-operated calcium channel (SOCC). Because after-depolarization of the myocyte is a major cause of cardiac arrhythmia, this discovery provides new approaches for treating and preventing heart disease. By down-regulating the activity of the ARCC or the SOCC, after-depolarization can be decreased and cardiac arrhythmia can be prevented, reduced, or eliminated. This can be accomplished using pharmaceuticals containing inhibitors of the ARCC or the SOCC, or by genetically modifying cells to reduce ARCC or SOCC activity. In addition, assays are disclosed using the ARCC or SOCC to discover potential anti-arrhythmic agents. Cellular and animal models of arrhythmia are disclosed in which the activity of the ARCC or SOCC is increased to promote after-depolarization and induce arrhythmia. | 2013-01-17 |
20130017199 | SIMULTANEOUS INHIBITION OF PD-L1/PD-L2 - Methods and compositions for treating an infection or disease that results from (1) failure to elicit rapid T cell mediated responses, (2) induction of T cell exhaustion, T cell anergy or both, or (3) failure to activate monocytes, macrophages, dendritic cells and/or other APCs, for example, as required to kill intracellular pathogens. The method and compositions solve the problem of undesired T cell inhibition by simultaneously inhibiting the PD-1 ligands, PD-L1 and PD-L2. The immune response can be modulated by providing antagonists which bind with different affinity, by varying the dosage of agent which is administered, by intermittent dosing over a regime, and combinations thereof, that provides for dissociation of agent from the molecule to which it is bound prior to being administered again. In some cases it may be particularly desirable to stimulate the immune system, then remove the stimulation. | 2013-01-17 |
20130017200 | MULTISPECIFIC ANTIBODIES, ANTIBODY ANALOGS, COMPOSITIONS, AND METHODS - Multispecific antibodies that specifically bind at least two different epitopes are provided. Structural variants of native antibodies (antibody analogs) are also provided. Also provided are multispecific antibodies and antibody analogs having a range of biological activities. Agonist and antagonist multispecific antibodies and agonist and antagonist antibody analogs are provided. Multispecific antibodies and antibody analogs conjugated with therapeutic and/or diagnostic agents are also provided, as are multispecific antibodies and antibody analogs conjugated with agents to increase in vivo half-life compared to multispecific antibodies and antibody analogs lacking such agents. In addition, methods of making multispecific antibodies and antibody analogs and compositions comprising multispecific antibodies and antibody analogs are provided. Therapeutic, research, and diagnostic uses of multispecific antibodies and antibody analogs are also provided. | 2013-01-17 |
20130017201 | BISPECIFIC MONOCLONAL ANTIBODY CAPABLE OF CROSS REACTING WITH LETHAL FACTOR (LF) AND EDEMA FACTOR (EF), AND NEUTRALIZING EDEMA TOXIN (ET) AS WELL AS LETHAL TOXIN (LT) OF BACILLUS ANTHRACISAANM Bhatnagar; RakeshAACI New DelhiAACO INAAGP Bhatnagar; Rakesh New Delhi INAANM Kulshreshtha; ParulAACI New DelhiAACO INAAGP Kulshreshtha; Parul New Delhi IN - The present invention relates to a monoclonal antibody (mAb) having capabilities of binding with lethal factor (LF) as well as edema factor (EF), and neutralizing lethal toxin (LT) as well as edema toxin (ET) of | 2013-01-17 |
20130017202 | Pharmaceutical compositions and methods of treatmentAANM Epshtein; Oleg IliichAACI MoscowAACO RUAAGP Epshtein; Oleg Iliich Moscow RUAANM Sergeeva; Svetlana AlexandrovnaAACI MoscowAACO RUAAGP Sergeeva; Svetlana Alexandrovna Moscow RUAANM Dolgovyh; Liudmila FyodorovnaAACI ChelyabinskAACO RUAAGP Dolgovyh; Liudmila Fyodorovna Chelyabinsk RUAANM Kheyfets; Irina AnatolievnaAACI DolgoprudnyAACO RUAAGP Kheyfets; Irina Anatolievna Dolgoprudny RUAANM Dugina; Julia LeonidovnaAACI MoscowAACO RUAAGP Dugina; Julia Leonidovna Moscow RUAANM Zabolotneva; Julia AlexandrovnaAACI MoscowAACO RUAAGP Zabolotneva; Julia Alexandrovna Moscow RUAANM Tarasov; Sergey AlexandrovichAACI GolitsynoAACO RUAAGP Tarasov; Sergey Alexandrovich Golitsyno RU - The present invention provides pharmaceutical compositions comprising an activated potentiated form of an antibody to human cannabinoid receptor and use in the treatment of obesity and related metabolic disorders. The present invention further provides pharmaceutical compositions comprising an activated potentiated form of an antibody to human cannabinoid receptor and activated potentiated form of an antibody to protein S-100 for use in the treatment of addiction to psychoactive substances. | 2013-01-17 |
20130017203 | METHODS OF TREATING AND PREVENTING STAPHYLOCOCCUS AUREUS INFECTIONS AND ASSOCIATED CONDITIONS - The present invention relates to methods and compositions for preventing and treating | 2013-01-17 |
20130017204 | Genes of an Otitis Media Isolate of Nontypeable Haemophilus Influenzae - The invention relates to the polynucleotide sequence of a nontypeable stain of | 2013-01-17 |
20130017205 | Inhibition of AXL Signaling in Anti-Metastatic Therapy - Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6. | 2013-01-17 |
20130017206 | MCAM MODULATION AND USES THEREOF - Methods, uses, agents and compositions useful for the diagnosis, prevention and/or treatment of inflammatory conditions, such as neuroinflammatory conditions such as multiple sclerosis, and for the identification and selection of inflammatory cytokine-secreting T cell or a precursor thereof, based on the expression and/or modulation of melanoma cell adhesion molecule (MCAM) are disclosed. | 2013-01-17 |
20130017207 | CHEMOTHERAPEUTIC METHODS AND COMPOSITIONS - Disclosed herein are methods and compositions for enhancing the cell-killing activity of anti-neoplastic agents by inhibiting the activity of a lysyl oxidase-type enzyme. Also disclosed are methods for screening for chemotherapeutic agents, and for molecules that enhance the activity of chemotherapeutic agents, using cells grown on an extracellular matrix. | 2013-01-17 |
20130017208 | Anti-IL-6 Antibodies, Compositions, Methods and Uses - An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. | 2013-01-17 |
20130017209 | A-BETA BINDING POLYPEPTIDES - The invention relates to biparatopic A-beta binding polypeptides and, more specifically, to biparatopic A-beta binding polypeptides comprising at least two immunoglobulin single variable domains binding to different epitopes of A-beta. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as Alzheimer's Disease. | 2013-01-17 |